about
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancerWFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lungCharacterisation and expression of SPLUNC2, the human orthologue of rodent parotid secretory proteinAcp. Best practice no 155. Pathological investigation of deaths following surgery, anaesthesia, and medical proceduresGenome-wide association studies identify four ER negative-specific breast cancer risk lociDifferential epithelial expression of the putative innate immune molecule SPLUNC1 in cystic fibrosisPre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision toolLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European DescentNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.High magnification chromoscopic colonoscopy or high frequency 20 MHz mini probe endoscopic ultrasound staging for early colorectal neoplasia: a comparative prospective analysis.Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.The use of digital imaging, video conferencing, and telepathology in histopathology: a national survey.Discriminant histological features in the diagnosis of chronic idiopathic inflammatory bowel disease: analysis of a large dataset by a novel data visualisation technique.Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.Endostatin gene variation and protein levels in breast cancer susceptibility and severity.Confocal endomicroscopy in ulcerative colitis: differentiating dysplasia-associated lesional mass and adenoma-like mass.In vivo confocal laser scanning chromo-endomicroscopy of colorectal neoplasia: changing the technological paradigm.In vivo real-time confocal laser scanning endomicroscopic colonoscopy for the detection and characterization of colorectal neoplasia.Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesMuch of the variation in breast pathology quality assurance data in the UK can be explained by the random order in which cases arrive at individual centres, but some true outliers do exist.Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancerGenetic variation in mitotic regulatory pathway genes is associated with breast tumor gradeCommon non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association ConsortiumMicroRNA related polymorphisms and breast cancer risk.Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study.Telepathology: current status and future prospects in diagnostic histopathology.Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors.Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general populationIdentification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer riskInherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.
P50
Q21134794-7012F00C-1A3D-45A9-B68C-36FD789DC2A4Q21284411-270255BA-EACA-4C36-B6F0-170C6BB3B838Q24317487-7C908328-BBE4-4923-9647-6FE8081819FDQ24563593-52E87CD0-85BE-492E-9E6C-7E89597381F1Q24622610-4CF459A1-C86E-4EB5-936C-004A1C57F1EEQ24649836-C4CF4B3F-D3CD-47D9-ADDD-8F2DCC0D51BBQ24670453-F0E8EC68-24FD-449A-A767-81C0365D3D7EQ29416989-28DCBBCE-2174-46CF-9431-5E50C379C43BQ29417100-A91A8670-8F7D-403E-8F3F-D0F5C0F0645DQ30000080-A13DFF2A-9F68-4121-A3E3-41D3E4D3287DQ30374367-772BC585-BD89-4CF9-89FB-274ED2585CA3Q30492850-201702BF-1850-4F56-B267-02AF4D77238EQ30660858-C9546D5A-779E-4A17-8AA6-AD12BD39ADE2Q31082788-76BE0224-EF52-433D-B4B4-317A1860C99EQ31135828-34038F86-2369-4F1E-945F-BCE95FF2DA70Q31150087-2D195016-E6A7-487D-B14B-EB0DB709652DQ32061776-2750DE69-3633-49EC-91D7-8F48C7AE4DFAQ33250259-CE75848F-E7CD-4F0F-ADA2-57BFD335C458Q33288626-2ABB8A40-2001-4574-BA64-2127F65DA9E9Q33293784-52417F15-307F-41C1-9618-C0228E9A96EEQ33300769-95B273A3-80F7-40DD-A3FC-7F6B028AF57CQ33322903-79FBB678-5F85-4839-8BE1-AA69E070A62DQ33330850-74245287-3C2F-444D-8BA9-16F489592F55Q33589487-37EA8B5E-1476-4F01-8885-6010493E3FD3Q33593016-4B8ABC4D-1593-48AC-8FF2-8BB0AA5A20FAQ34015159-C95D2E82-58BE-4700-B822-FDE6ABB0C1EDQ34181322-10F0642A-9B75-4089-AC19-8C0433AD7C85Q34378972-7F81A580-F033-42F9-B645-72E69FB09DC2Q34379032-B32CE34D-1826-485C-9523-4E8CDDFA2831Q34497352-4B8D5C84-73A2-4529-BB55-31D001842817Q34613673-020062A3-ABA3-44C7-A530-49CBC650819DQ34765948-C7E1CF88-3DB0-49B2-B6AB-A3C2E3FEC2ACQ34898735-0207833B-11C5-430D-93AD-CAE4EB10D155Q34903062-51078B3A-EBA7-498F-AC44-400A0F39A6C7Q34996647-3A939E35-F6F9-4966-9E61-FAC44D98E981Q35022847-FD652AA3-6349-41B5-A11E-5815768BED20Q35064451-14F075BC-04D9-4B36-8159-0DFB8486BD7DQ35089479-35E198E5-F204-4A3B-B33B-F9E81FF08417Q35102646-8D651D9E-DD8E-403B-9079-2A801FE69D22Q35104068-8A0F3BF5-5C15-404B-90F0-F4FB60DBEAE3
P50
description
hulumtues
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Simon Cross
@fr
Simon S Cross
@br
Simon S Cross
@ca
Simon S Cross
@cs
Simon S Cross
@cy
Simon S Cross
@da
Simon S Cross
@de
Simon S Cross
@de-at
Simon S Cross
@de-ch
Simon S Cross
@en-ca
type
label
Simon Cross
@fr
Simon S Cross
@br
Simon S Cross
@ca
Simon S Cross
@cs
Simon S Cross
@cy
Simon S Cross
@da
Simon S Cross
@de
Simon S Cross
@de-at
Simon S Cross
@de-ch
Simon S Cross
@en-ca
altLabel
Simon Cross
@en
prefLabel
Simon Cross
@fr
Simon S Cross
@br
Simon S Cross
@ca
Simon S Cross
@cs
Simon S Cross
@cy
Simon S Cross
@da
Simon S Cross
@de
Simon S Cross
@de-at
Simon S Cross
@de-ch
Simon S Cross
@en-ca
P106
P1153
35993775100
P2031
1989-01-01T00:00:00Z
P21
P31
P496
0000-0003-2044-1754